MedTrace Logo

Impact of P53 and SIRT1 in Type 2 Diabetes

NCT03925714 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2019-04-24

No results posted yet for this study

Summary

Investigating the impact of p53 and SIRT1 in the development of type 2 DM

Conditions

  • DM

Interventions

OTHER

life style

life sryle control only

DRUG

Metformin

metformin twice daily

DRUG

Nigetella salivata

NS twice daily

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Eman SA Sawan, Msc · Tanta University - Faculty of Pharmacy

  • Sahar Hegazy, Prof · Tanta University - Faculty of Pharmacy

  • Tarek Mostafa, ass. Prof. · Tanta University - Faculty of Pharmacy

  • Sherin El-Nidany, MD · Tanta University-Faculty of pharmacy

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2028-12-31
Completion
2028-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03925714 on ClinicalTrials.gov